Please login to the form below

Not currently logged in
Email:
Password:

dermatology

This page shows the latest dermatology news and features for those working in and with pharma, biotech and healthcare.

New data keeps AbbVie’s star pipeline therapies on track

New data keeps AbbVie’s star pipeline therapies on track

AbbVie has presented new data on its risankizumab candidate in psoriasis and upadacitinib in atopic dermatitis that suggest it has a potentially lucrative dermatology franchise on the way. ... At the European Academy of Dermatology and Venereology (EADV)

Latest news

  • Novartis sells off part of Sandoz portfolio Novartis sells off part of Sandoz portfolio

    The move, which will see Sandoz do away with its US dermatology and generic oral solid portfolios, allows the firm to re-focus its pipeline, says the unit's chief executive ... In return Aurobindo is set to receive approximately 300 products, as well as

  • Realm toppled by second mid-stage trial flop Realm toppled by second mid-stage trial flop

    The company also thinks that its hypochlorous acid formulations could have potential “in immune-mediated diseases generally, ”although programmes outside of dermatology are at the very early stages of development.

  • FDA gives breakthrough status to Xolair for food allergies FDA gives breakthrough status to Xolair for food allergies

    Since then Roche and Novartis have built on the drug’s approved uses, expanding its label in allergic asthma and adding a dermatology indication – the treatment of chronic idiopathic urticaria (hives) –

  • Almirall acquires Allergan’s dermatology portfolio for $650m Almirall acquires Allergan’s dermatology portfolio for $650m

    Almirall acquires Allergan’ s dermatology portfolio for $650m. The pharma group buys four products along with Allergan's first-in-class antibiotic Seysara. ... In a deal worth $650m, Spanish pharmaceutical company Almirall is set to buy Allergan’s

  • Sun Pharma passes milestone with novel psoriasis drug approval Sun Pharma passes milestone with novel psoriasis drug approval

    With the approval of Ilumya and our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis, ”said Sun

More from news
Approximately 12 fully matching, plus 178 partially matching documents found.

Latest Intelligence

  • Leo has its eyes on the prize Leo has its eyes on the prize

    More than a century has passed since the Nobel Prize in Medicine was awarded for dermatology. ... There are huge unmet needs and the predictions are that the dermatology market will grow significantly over the coming years.

  • Deal Watch January 2018

    Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China).

  • Pharma deals continue to slide Pharma deals continue to slide

    Roche has licensed a monoclonal antibody in phase II to Dermira, a dermatology company.

  • Deal Watch September 2016 Deal Watch September 2016

    The Vitae acquisition builds Allergan's dermatology pipeline with VTP-43742, a mid stage, orally active RORγt (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis,

  • Deal Watch August 2016 Deal Watch August 2016

    So the product, which is an orphan drug, ended up in the portfolio of a $10bn company focussed on GI, dermatology and neurology and which was under investigation by the SEC

More from intelligence
Approximately 0 fully matching, plus 35 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 26 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics